Literature DB >> 26250437

The development of the vanderbilt pediatric dizziness handicap inventory for patient caregivers (DHI-PC).

Devin L McCaslin1, Gary P Jacobson2, Warren Lambert3, Lauren N English2, Alison J Kemph2.   

Abstract

PURPOSE: The purpose of the present investigation was to develop a psychometrically sound dizziness disability/handicap outcome measure for use with a pediatric population between 5 and 12 years of age.
METHODS: Items comprising Phase 1 of the DHI-PC were created based on reports from parents, providers and patients. This version was administered to the caregivers (mean age 31.6 years, sd 5 years, 74 female) of 86 pediatric patients (mean age 9 years, sd=2.83 years, 45 female). The caregiver's responses to each item were limited to "yes" (scored as 4 points), "sometimes" (scored as 2 points) or "no" (scored as zero points).
RESULTS: A factor analysis for Phase 1 of the scale showed there to be a single factor (eigenvalue of 11.51) that explained 29% of the total variance. The results of Cronbach's alpha analysis enabled us to eliminate 15 items reducing the scale to 25 items (i.e. Phase 2 of the DHI-PC). Following elimination of the items with low item-total coefficients, the second phase of the DHI-PC was administered to 56 legal guardians (mean patient age 8 years, sd 4.65 years, 37 female). The analysis of this data again showed there to be a single factor (eigenvalue of 8.30) that explained 33% of the variance. Four items demonstrated item-total correlations less than 0.40. The final version of the DHI-PC has 21 items and a maximum score of 84%. Short-term test-retest reliability (i.e. three week interval between test and retest) of this DHI-PC was assessed for a subset of 10 patients (caregivers, mean age 38 years, sd=7 years, 10 female). The results indicated the short-term, test-retest reliability to be strong (r=0.98, p≤0.001).
CONCLUSION: The DHI-PC represents a new tool for assessing the impact of pediatric dizziness on the patient (as viewed through the perspective of the caregiver). This tool may be incorporated into the comprehensive evaluation of children suffering from dizziness.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dizziness; Handicap; Pediatric; Vestibular

Mesh:

Year:  2015        PMID: 26250437     DOI: 10.1016/j.ijporl.2015.07.017

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  6 in total

1.  Prevalence of abnormal vestibular responses in children with sensorineural hearing loss.

Authors:  Erik Gadsbøll; Alexander Wolfhagen Erbs; Dan Dupont Hougaard
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-14       Impact factor: 3.236

Review 2.  Quantitative Vestibular Function Testing in the Pediatric Population.

Authors:  Kristen L Janky; Amanda I Rodriguez
Journal:  Semin Hear       Date:  2018-07-20

Review 3.  Considerations for Testing and Treating Children with Central Vestibular Impairments.

Authors:  Jennifer B Christy
Journal:  Semin Hear       Date:  2018-07-20

Review 4.  Development of a Pediatric Balance Center: A Multidisciplinary Approach.

Authors:  Katheryn Bachmann; Violette Lavender; Micheal Castiglione
Journal:  Semin Hear       Date:  2018-07-20

5.  Determining the prevalence of vestibular screening failures in pediatric cancer patients whose therapies include radiation to the head/neck and platin-based therapies: A pilot study.

Authors:  Miranda L Camet; Susan S Hayashi; Belinda C Sinks; Jennifer Henry; Katie Gettinger; Ashley Hite; Juliann Kiefer; Caroline Mohrmann; Taryn Sandheinrich; Feng Gao; Robert J Hayashi
Journal:  Pediatr Blood Cancer       Date:  2018-01-30       Impact factor: 3.167

6.  Visually Induced Dizziness in Children and Validation of the Pediatric Visually Induced Dizziness Questionnaire.

Authors:  Marousa Pavlou; Susan L Whitney; Abdulaziz A Alkathiry; Marian Huett; Linda M Luxon; Ewa Raglan; Emma L Godfrey; Doris-Eva Bamiou
Journal:  Front Neurol       Date:  2017-12-05       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.